Evan Y. Yu, MD, discusses how the presentation of a patient with metastatic castration-resistant prostate cancer (mCRPC) involves evaluating factors such as disease progression despite androgen deprivation therapy, symptoms, prior treatments, and performance status to guide the selection of appropriate therapeutic strategies for managing this advanced disease state.
Evan Y. Yu, MD, discusses how adding chemotherapy to a doublet regimen for metastatic hormone-sensitive prostate cancer may be considered on an as-needed basis, particularly for patients with high disease burden or rapid progression, while carefully weighing the potential benefits and risks of intensifying therapy.
James J. Harding, MD, discusses how the initial findings from CheckMate 9DW inform the role of nivolumab plus ipilimumab (NIVO + IPI) in the first-line (1L) treatment landscape for unresectable hepatocellular carcinoma (uHCC), considering factors such as efficacy, safety, and patient characteristics (eg, age) when selecting between first-line systemic immunotherapy (IO) regimens.
Panelists discuss the PATINA study, examining the role of palbociclib in combination with letrozole as a first-line treatment for hormone receptor–positive, HER2-negative breast cancer, and its impact on progression-free survival.
Panelists discuss the findings from the DESTINY-Breast12 study, focusing on the efficacy and safety of trastuzumab deruxtecan in patients with HER2-low breast cancer and its potential to expand treatment options for this subgroup.
Panelists discuss the results and implications of the DESTINY-Breast06 study, highlighting the efficacy of trastuzumab deruxtecan in patients with HER2-positive breast cancer previously treated with multiple lines of therapy.
The panelist discusses how the treatment landscape for early-stage relapsed/refractory multiple myeloma (R/R MM) has evolved significantly with CAR T-cell therapies (idecabtagene vicleucel, ciltacabtagene autoleucel [ide-cel, cilta-cel]) and novel drug combinations. Treatment selection now considers prior therapies, patient characteristics, and response duration. For third-line chimeric antigen receptor (CAR) T after no prior CAR T use, cilta-cel shows favorable efficacy data with deeper, more durable responses than ide-cel, though both are viable options.
The panelist discusses how the patient had triplet therapy 6 years ago, which was the standard for myeloma treatment at the time. Since then, the patient has had a biochemical relapse, renal insufficiency, and moderate anemia, so he needs therapy but not immediate therapy.
A panelist discusses how, despite recent advances in relapsed/refractory follicular lymphoma treatment, important unmet needs are being addressed through ongoing trials while reflecting on proud accomplishments in the field and expressing enthusiasm for developments in the coming year.
Panelists discuss how the CEPHEUS trial demonstrates the comparative efficacy and safety of subcutaneous daratumumab combined with VRd vs VRd alone in patients with transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma, highlighting key outcomes and clinical implications.
Experts examine the potential role of chimeric antigen receptor (CAR) T-cell therapy in chronic lymphocytic leukemia treatment, incorporating new evidence presented at the 66th American Society of Hematology Annual Meeting and Exposition 2024.
A panelist discusses adverse events with amivantamab and provides new recommendations for managing these skin-related events.
Thomas W. LeBlanc, MD, MA, discusses how existing challenges in treatment choices for low-risk myelodysplastic syndromes (LR-MDS) include limited access to newer therapies, patient-specific factors, and treatment sequencing complexities, and explores strategies to address these barriers, such as improving health care access, optimizing patient selection, and enhancing treatment guidelines.
Panelists discuss treatment options for patients ineligible for chimeric antigen receptor T-cell therapy in the second-line setting, focusing on the selection of new proteasome inhibitors and/or immune-mediated immunomodulatory drugs vs recycling combination regimens, and reviewing recent data from the APOLLO and IKEMA trials that support the use of combination therapies in relapsed/refractory multiple myeloma.
Panelists discuss the correlation between early and late toxicities observed in clinical practice for patients receiving chimeric antigen receptor T-cell (CAR T) therapy in early relapsed/refractory multiple myeloma and their perceptions of the latest International Myeloma Working Group Consensus Guidelines on response assessment and management of CAR T–related adverse events.
Evan Y. Yu, MD, discusses how community oncologists can critically weigh the evidence from studies on androgen deprivation therapy plus androgen receptor pathway inhibitors regimens by considering factors such as efficacy, safety, patient comorbidities, and treatment preferences, and how the collective trial results guide individualized treatment decision-making to optimize outcomes for patients with metastatic hormone-sensitive prostate cancer.
James J. Harding, MD, compares the responses observed with nivolumab plus ipilimumab (NIVO + IPI) therapy in the CheckMate 9DW trial to other first-line (1L) immunotherapy (IO) regimens for unresectable hepatocellular carcinoma (uHCC), including the HIMALAYA 5-year update (STRIDE) and the IMbrave150 trial (atezolizumab [ATEZO] + bevacizumab [BEV]), highlighting differences in efficacy and treatment outcomes.
Evan Y. Yu, MD, discusses how safety data for first-line androgen deprivation therapy plus androgen receptor pathway inhibitors (ARPI) regimens such as darolutamide, abiraterone, enzalutamide, and apalutamide reveal clinically relevant distinctions in their safety profiles, including the most common and challenging toxicities, incidence of grade 3 or higher adverse events, treatment discontinuations, and potential drug-drug interactions. He highlights key factors that influence treatment choice and disease management in patients with metastatic hormone-sensitive prostate cancer.
Panelists provide an overview of the EMBER-3 trial and its key findings.
Panelists provide an overview of the PADMA trial and its key findings.
Panelists provide an overview of the TAILORx trial and its key findings.
Panelists provide an overview of the EUROPA trial and its key findings.
Panelists discuss key learnings from recent studies on lower-risk myelodysplastic syndrome (LR-MDS) treatment, identify remaining knowledge gaps, and offer final takeaways, including their thoughts on the role of luspatercept in the evolving LR-MDS treatment landscape, clinical pearls for community oncologists, and major unanswered questions that could improve outcomes for LR-MDS and anemia management in the future.
Panelists discuss second-line (2L) treatment strategies for lower-risk myelodysplastic syndrome (LR-MDS), focusing on how to choose a 2L treatment for patients refractory to first-line options, and provide an overview of recent updates from the IMerge trial (Santini et al, EHA 2024; Zeidan et al, JCO 2024), while considering the role of imetelstat in treatment sequencing according to NCCN Guidelines MDS-5.
Hope S. Rugo, MD, FASCO, discusses key takeaways from SABCS 2024 conference.
A panelist discusses how various antibody-drug conjugates, including polatuzumab vedotin, pinatuzumab vedotin, and loncastuximab, have been studied in combination with rituximab for relapsed/refractory follicular lymphoma. Recent data from ASH 2024 highlight important patient considerations for these treatment approaches.
Experts discuss the comparative efficacy of sonrotoclax plus zanubrutinib vs venetoclax in chronic lymphocytic leukemia treatment based on updates presented at the 66th American Society of Hematology Annual Meeting and Exposition 2024.
Panelists discuss how guideline-recommended treatment regimens for patients with transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma should be evaluated and selected based on patient characteristics, efficacy data, and safety profiles to achieve optimal outcomes.
Thomas W. LeBlanc, MD, MA, discusses how erythroid maturation agents (EMAs), such as luspatercept, are increasingly important in the anemia management landscape for low-risk myelodysplastic syndromes (LR-MDS), with a focus on achieving hemoglobin levels ≥ 10, as highlighted by Santini et al in their ASH 2024 abstract, demonstrating the clinical significance of this target for improving patient outcomes.
Aimee Merino, MD, discusses how the latest efficacy outcomes from the CARTITUDE-4 trial, evaluating ciltacabtagene autoleucel (cilta-cel) in relapsed/refractory multiple myeloma, have influenced her approach to patient selection and referral for chimeric antigen receptor T-cell therapy in early relapse cases.